Three-Year Overall Survival of Patients With Advanced Non–Small-Cell Lung Cancers With ≥50% PD-L1 Expression Treated With First-Line Pembrolizumab Monotherapy in a Real-World Setting (ESCKEYP GFPC Study).

Details

Language :

English

ISSN :

15249557

Volume :

47

Issue :

1

Database :

Complementary Index

Journal :

Journal of Immunotherapy

Publication Type :

Academic Journal

Accession number :

174081509

Full Text :

https://doi.org/10.1097/CJI.0000000000000490